$7600 | Site License
$16700 | Global License

Future Horizons and Growth Strategies in the Japanese Clinical Chemistry and Immunodiagnostic Markets: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities
[Report Updated: 02-08-2016]

Published by Venture Planning Group (VPG): 02 Aug 2016 | 60109 | In Stock
Related Topics: Abbott , Blood , Chemistry , Cholesterol , Protein , Roche

Introduction

Complete report ,600.  DataPack (test volumes, sales forecasts, supplier shares) ,900.

VPG Market Research's new report is a strategic analysis of major business opportunities emerging in the Japanese clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the Japanese market; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.

The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables.

Rationale

The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.

Strategic Recommendations

- New product development opportunities
with significant market appeal.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Competitive Assessments

- Strategic assessments of major suppliers and
emerging market entrants, including their sales, product
portfolios, marketing tactics, collaborative
arrangements and new products in R&D. 

- The companies analyzed in the report include
Abbott, AdnaGen, Agilent, Bayer, Beckman Coulter/Danaher, Biomedical Diagnostics, bioMerieux, Bio-Rad, DiaSorin, Eiken, Fujirebio, Grifols IL, Kyowa Medex, Matritech/Alere, Ortho-Clinical Diagnostics, Quest Diagnostics, Roche, Siemens, Sysmex, Thermo Fisher, Tosoh, Wako, Wallac/PE.

Tests Analyzed in the Report:

Routine Clinical Chemistry

Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total,
BUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride,
Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Ferritin, GGT, Glucose,
HDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus,
Potassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid.

Therapeutic Drug Monitoring (TDM)

Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam,
Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus,
Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.

Endocrine Function

Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,
Prolactin, T3, T3 Uptake,  Free T3, T4, Free T4, TBG, Testosterone,
Thyroglobulin Ab,  TPO Ab, TSH.

Tumor Markers and Special Chemistry

AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid),
Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood,
PAP, PSA, Thyroglobulin, Vitamin B-12.

Immunoproteins

C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM,
Immunofixation, Prealbumin, Protein Electrophoresis.

Drugs of Abuse

Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,
LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP),
Propoxyphene, Tricyclic Antidepressants.

Market Segmentation Analysis

- Comprehensive review of the market
dynamics, trends, structure, size, growth,
and key suppliers.

- Test volume and sales forecasts for over 100 clinical chemistry,
TDM, endocrine, cancer, immunoprotein and abused drug assays,
by market segment:
    
     ° Hospitals
     ° Commercial/Private Laboratories

Current and Emerging Products

- Analysis of current and emerging clinical chemistry
and immunodiagnostic tests.

- Review of current instrumentation technologies, and feature comparison
of high-, medium-, and low-volume/POC analyzers.

Technology Review

- Assessment of current and emerging
technologies, and their potential  market applications.

- Comprehensive lists of companies developing
or marketing new technologies and products by test.

Contains 559 pages and 103 tables

Table of Contents
for Future Horizons and Growth Strategies in the Japanese Clinical Chemistry and Immunodiagnostic Markets: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities [Report Updated: 02-08-2016]

  • Table of Content - click REQUEST A SAMPLE BUTTON

List Of Tables
in Future Horizons and Growth Strategies in the Japanese Clinical Chemistry and Immunodiagnostic Markets: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities [Report Updated: 02-08-2016]

Competitive Assessments

- Abbott Laboratories

- AdnaGen/Alere

- Agilent Technologies

- Bayer Healthcare

- Beckman Coulter/Danaher

- Biomedical Diagnostics

- BioMerieux

- Bio-Rad

- DiaSorin

- Eiken

- Fujirebio

- Grifols

- Instrumentation Laboratory

- Kyowa Medex

- Matritech/Alere

- Ortho-Clinical Diagnostics

- Quest Diagnostics

- Roche

- Siemens

- Sysmex

- Thermo Fisher

- Tosoh

- Wako

- Wallac/PE

Additional Details

Publisher

Venture Planning Group (VPG)

Publisher Information

Reference

60109 | VPCC20267

Number of Pages

559

Report Format

PDF

Venture Planning Group (VPG) Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Designs on the Future of Health: The ambitions of Google, Apple, et al
IntroductionThe digital health revolution: tech giants and their impact on pharmaDrug discovery, qui...
01 Mar 2016 by FirstWord Pharma USD $695 More Info
The Future of Biosimilars 2015
IntroductionThe Future of Biosimilars 2015 offers expert insight and opinion on the key issues facin...
01 Jun 2015 by FirstWord Pharma USD $2,195 More Info
Orphan Drug Market Access: Payer Insights on the Present and Future
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
14 Oct 2014 by FirstWord Pharma USD $695 More Info
The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus
IntroductionThere has been considerable media hype and clinical interest in cancer immunotherapy in ...
01 Jul 2014 by FirstWord Pharma USD $4,995 More Info
Physician Views: What does the future hold for new EGFR targeting NSCLC therapies?
Scope Propelled via momentum from new data presented at the ASCO annual meeting, AstraZeneca's AZD-9...
19 Jun 2014 by FirstWord Pharma USD $695 More Info
The Future of Biosimilars: mapping critical uncertainties and the impact of future events
IntroductionThe Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Event...
05 May 2014 by FirstWord Pharma USD $1,950 More Info
Physician Views: What future for wearable health technology?
Scope As the patient becomes a more proactive stakeholder in the healthcare sphere and the developme...
24 Apr 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What role will device development play in the future GLP-1 agonist market?
Scope Positioned frequently as a transitional diabetes therapy between oral agents and insulin – and...
07 Mar 2014 by FirstWord Pharma USD $695 More Info
Pharma's Future Role in CME
IntroductionOver the last 10 years, every aspect of continuing medical education (CME) has endured m...
01 Aug 2012 by FirstWord Pharma USD $695 More Info
Branded Generics in South East Asia: Current and Future Opportunities
IntroductionWith its fast-growing, young population and projected pharmaceutical sales in excess of ...
01 Apr 2012 by FirstWord Pharma USD $945 More Info

This report is published by Venture Planning Group (VPG)

Download Free Report Summary PDF

Future Horizons and Growth Strategies in the Japanese Clinical Chemistry and Immunodiagnostic Markets: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities [Report Updated: 02-08-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...